Dermata Therapeutics Q3 EPS $(0.54) Beats $(0.63) Estimate
Portfolio Pulse from Benzinga Newsdesk
Dermata Therapeutics (NASDAQ:DRMA) reported Q3 losses of $(0.54) per share, beating the analyst consensus estimate of $(0.63) by 14.29%. This represents an 83.13% increase over losses of $(3.20) per share from the same period last year.
November 09, 2023 | 10:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dermata Therapeutics reported better than expected Q3 losses, which could positively impact investor sentiment.
Dermata Therapeutics reported a smaller loss than expected for Q3, beating analyst estimates by 14.29%. This is a significant improvement from the same period last year, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100